---
document_datetime: 2025-12-19 12:25:40
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pregabalin-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: pregabalin-viatris-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.6265921
conversion_datetime: 2025-12-22 12:53:35.195276
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pregabalin Viatris

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Article 61(3) /      | - Notification acc. Article 61(3) - Accepted | 19/12/2025                          |                                             | PL                               |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000319152                      | Update of the package leaflet with revised contact details of local representative.                                                                                                                                                                                                                                                                                                                                             |            |     |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IA / EMA/VR/0000316987 | This was an application for a group of variations. B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an | 12/12/2025 | N/A |
| Variation type IA / EMA/VR/0000293003 | B.II.d.2 Change in test procedure for the finished product - B.II.d.2.a Minor changes to an approved test procedure - Accepted                                                                                                                                                                                                                                                                                                  | 25/08/2025 | N/A |
| Variation type IA / EMA/VR/0000288609 | This was an application for a group of variations. B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                                                                                           | 30/07/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                          | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted                                                                                                                                                                           |            |     |                 |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|
| Variation type IB / EMA/VR/0000268655    | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.e) Container closure system - B.II.e.z Other variation - Accepted                                                                                                                                                                                                                            | 10/07/2025 | N/A |                 |
| Variation type IA_IN / EMA/VR/0000252315 | This was an application for a group of variations. B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.3 Updated certificate from an already approved manufacturer - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.3 | 06/03/2025 |     | Annex II and PL |

<div style=\"page-break-after: always\"></div>

|                                       | Updated certificate from an already approved manufacturer - Accepted B.III.1.b European Pharmacopoeial TSE Certificate of suitability for an active substance/starting material/reagent/ intermediate/or excipient - B.III.1.b.3 Updated certificate from an already approved manufacturer - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.a The activities for which the manufacturer/importer is responsible include batch release - Accepted A. ADMINISTRATIVE CHANGES - A.7 Deletion of manufacturing sites for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the   |            |     |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type IB / EMA/VR/0000241422 | This was an application for a group of variations. B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate /                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 24/01/2025 | N/A |

<div style=\"page-break-after: always\"></div>

|                                       | reagent used in the manufacturing process of the active substance - B.I.b.1.h Addition or replacement (excluding biological or immunological substance) of a specification parameter with its corresponding test method as a result of a safety or quality issue - Accepted B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.3 New certificate from a new manufacturer (replacement or addition) - Accepted                                                                                    |            |      |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|
| Variation type IB / EMA/VR/0000231406 | This was an application for a group of variations. A. ADMINISTRATIVE CHANGES - A.6 Change in ATC Code / ATC Vet Code - Accepted C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted C.I.2.a - To update section 4.4 of the SmPC in order to add information on potential | 03/12/2024 | SmPC |

<div style=\"page-break-after: always\"></div>

|                                                         | abuse in recreational drug users, following assessment of the same change in the reference product. A.6 - To change the ATC code from N03AX16 to N02BF02. Furthermore, the Marketing Authorisation Holder has taken the opportunity to implement editorial changes in the following translations: MT, RO, SK, FI, CS, IS, SL and PT.                                                                                                                              |            |            |                        |
|---------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| Marketing Authorisation Transfer - H / EMA/T/0000177721 | - Transfer of a marketing authorisation - Transfer of Marketing Authorisation from Mylan Pharmaceuticals Limited to Viatris Limited.                                                                                                                                                                                                                                                                                                                              | 31/05/2024 | 24/07/2024 | SmPC, Labelling and PL |
| Variation type IA_IN / EMA/VR/0000174634                | A.2 Change in the (invented) name of the medicinal product - A.2.a) for Centrally Authorised products - Accepted                                                                                                                                                                                                                                                                                                                                                  | 18/04/2024 | 19/07/2024 | SmPC, Labelling and PL |
| Variation type IB / EMA/VR/0000167464                   | C.I.2 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid/biosimilar medicinal products following assessment of the same change for the reference product - C.I.2.a Implementation of change(s) for which no new additional data is required to be submitted by the MAH - Accepted To update the SmPC sections 4.4 and 4.8 and section 3 in the PIL with 'suicidal ideation' as part of the observed withdrawal | 23/02/2024 | 19/07/2024 | SmPC and PL            |

<div style=\"page-break-after: always\"></div>

| symptoms. In addition The MAH has taken this opportunity to amend the local representatives in Belgium, Luxembourg, Baltics, Greece, Spain, Italy, Croatia and Hungary. Also the DA, NL and LT have been corrected to be fully in line with the annexes of the reference product.   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|